Src plays an important role in cell proliferation, differentiation, adhesion, and migration. Altered Src activity has been strongly implicated in the development, growth, progression, and metastasis of human cancers. We have analysed the change and regulation of Src upon cell detachment in anoikis-resistant human lung adenocarcinoma cells and compared with that of relatively normal and anoikis-sensitive epithelial cells. We found that Src activity was increased in the anoikis-resistant lung tumor cells when they were detached and cultured in suspension. The detachment-induced Src activation in the tumor cells compensates for the loss of cell survival signals caused by disruption of cell-matrix interactions and contributes to anoikis resistance of the tumor cells. Pyk2, rather than PI 3K/Akt or Erk, appears to be the key downstream effecter of Src in mediating the cell survival signals. The increased Src activity is mainly due to the phosphorylation of Tyr-419, rather than the dephosphorylation of Tyr-530 of Src protein. PDGFR, not FAK or EGFR, appears to be the upstream protein tyrosine kinase responsible for the detachment-induced Src activation in the lung tumor cells. The increased Src activity upon cell detachment may contribute to the metastasis potential of malignant tumors.
Introduction
Src was initially discovered as the oncogenic protein (v-Src) of the retrovirus Rous sarcoma virus. Later, the cellular counterpart of Src, c-Src, was identified (Collett et al., 1979; Oppermann et al., 1979) . The Src family includes Src, Lyn, Fyn, Yes, Hck, Fgr, Blk, and Lck. An important mechanism for regulation of c-Src tyrosine kinase activity is through control of its phosphorylation status. There are two major phosphorylation sites present in the C-terminus of human c-Src, Tyr-419 (Tyr-416 in chicken) and Tyr-530 (Tyr-527 in chicken) (Bjorge et al., 2000; Jones et al., 2000) . Tyr-530/527 is the negative regulatory site of Src. When this site becomes phosphorylated, Src undergoes a conformational change whereby phosphotyrosine-530/527 interacts with its own SH2 domain rendering the Src protein catalytically inactive. Tyr-419/416 is the positive regulatory site for Src. When this site becomes phosphorylated, it is displaced from the substrate binding pocket, allowing the kinase access to substrate and making Src activated (Xu et al., 1997 (Xu et al., , 1999 .
Src is one of the key protein tyrosine kinases involved in cell survival and growth (Schlessinger, 2000) . There have been many studies showing that Src protein level or its kinase activity is increased in a variety of human cancers, such as lung cancer (Mazurenko et al., 1992) , breast cancer (Jacobs and Rubsamen, 1983; Muthuswamy et al., 1994; Verbeek et al., 1996; Egan et al., 1999) , colon cancer (Bolen et al., 1987; Cartwright et al., 1989 Cartwright et al., , 1990 Cartwright et al., , 1994 Weber et al., 1992; Termuhlen et al., 1993; Windham et al., 2002) , pancreatic cancer (Lutz et al., 1998) , ovarian cancer (Budde et al., 1994; Wiener et al., 1999) , neural cancer (Bolen et al., 1985; Bjelfman et al., 1990) , esophageal cancer (Kumble et al., 1997) , gastric cancer (Takeshima et al., 1991) , melanoma (Bjorge et al., 1996) , and Kaposi's sarcoma (Munshi et al., 2000) . All these studies suggest that Src plays important roles in the occurrence and development of human cancers. There are also evidences suggesting that Src may be related to the metastatic phenotype of cancers. A role for Src in tumor progression and metastasis is poignantly illustrated by observations that Src activity increases with the progression of colon tumors, being higher in primary tumors than in polyps, and higher yet in metastatic liver lesions . It has been reported that endogenous Src expression is increased in secondary tumors compared with their primary counterparts in an animal model of colorectal cancer metastasis (Mao et al., 1997) . Src activity is elevated in highly metastatic colon cancer cells when compared to poorly metastatic colon tumor cells (Mao et al., 1997) . It has also been found that Src activity in synchronous tumors is higher in liver metastases than in primary tumors (Termuhlen et al., 1993) . However, the exact role of Src in tumor progression and metastasis has not been fully elucidated.
Anoikis is a type of apoptosis induced by detachment of adherent cells from their substratum and is a useful model to study the mechanisms of Src in tumor progression and metastasis. To understand whether and how Src functions to prevent human cancer cells from anoikis, we analysed the regulation and function of Src during cell detachment in a number of anoikisresistant human lung cancer cell lines and compared with that of anoikis-sensitive lung and other relatively normal epithelial cells. We found that the regulation of Src was altered upon cell detachment in all the human lung cancer cells we have analysed. There is a dramatic increase of Src activity in the anoikis-resistant tumor cells when they are detached from their substratum and cultured in suspension. This increased Src activity is critical for the tumor cells to survive in suspension. This study provides new insights into the function and mechanism of Src in cancer tumorigenesis and metastasis.
Results

Protein tyrosine kinase activities are increased by cell detachment in lung cancer cells
Our previous study has shown that the lung tumor cells are generally resistant to anoikis and that tyrosine kinase-mediated cell survival signals are responsible for the anoikis resistance of the lung tumor cells (Wei et al., 2001) . To further explore the role of protein tyrosine kinases in anoikis resistance of tumor cells, we measured the tyrosine kinase activities of the total cell lysates of the lung adenocarcinoma cells and compared with that of a nontransformed anoikis-sensitive epithelial cell line, MDCK, using a GST-p130Cas protein as a substrate (Figure 1 ). The total protein tyrosine kinase activities towards the GST-p130Cas were higher in the lung tumor cells than that in the anoikis-sensitive cells. More importantly, the tyrosine kinase activities in the anoikisresistant lung tumor cells were increased dramatically when they were detached and cultured in suspension. In contrast, the tyrosine kinase activities in the anoikissensitive MDCK cells were decreased after detachment (Figure 1) . Our previous data have demonstrated that abolishing the protein tyrosine kinase (PTK) activity with the PTK inhibitor, genistein, could induce anoikis in the lung tumor cells (Wei et al., 2001) . These data strongly suggest that protein tyrosine kinases play an important role in the lung tumor cells' resistance to anoikis.
Src activity is increased in lung adenocarcinoma cells upon cell detachment FAK and Src are the two major protein tyrosine kinases of p130Cas in the focal adhesion complex, both of which are also regulated by cell adhesion. To distinguish which one may be responsible for the altered tyrosine kinase activities towards p130Cas in the tumor cells, we analysed their association with p130Cas in the lysates of attached versus detached cells. We observed two differences between the anoikis-sensitive nontransformed cells versus the anoikis-resistant tumor cells. First, the major kinase associated with p130Cas in the lung tumor cells (A549 and H1792) was Src, whereas it was FAK in the nontransformed cells (MDCK). Second, the amount of Src associated with p130Cas was increased in the lung tumor cells upon cell detachment, whereas that of FAK was decreased in the nontransformed cells (Figure 1 ). The increased Src association with p130Cas in the tumor cells correlated with the increased kinase activities towards p130Cas in these cells upon detachment. The protein levels of Src and FAK were similar in the nontransformed and tumor cells (Figure 2a ). These data suggest that Src, rather than FAK, might be the protein tyrosine kinase responsible for the detachment-induced increase of kinase activity in the lung tumor cells.
To further understand the roles of FAK and Src in the tumor cell anoikis resistance, we analysed the regulation of their phosphorylation, which reflects their activities, during cell detachment in more cell lines. Two of them, namely MDCK and HBE4-E6/E7, are immortalized but nontransformed anoikis-sensitive epithelial cells. Calu-3, although a lung cancer cell line, is also anoikis-sensitive. The rest are six anoikis-resistant lung adenocarcinoma Figure 1 p130Cas-associated tyrosine kinase activities and kinases of human lung cancer cell lysates. Anoikis-sensitive MDCK cells and lung adenocarcinoma cells A549 and H1792 were cultured as attached (A) or in suspension (S) for 6 h (S6) or 24 h (S24). The cells were then lysed and the total cells lysates were incubated with a p130Cas/GST fusion protein conjugated to Glutathionine-Agarose beads in kinase assay buffer at 371C for 30 min. After reaction, the p130cas/GST fusion protein beads were isolated and resuspended with Lamaeli sample buffer and analysed by immunoblotting using the antibodies to phospho-tyrosine (4G10), FAK, Src, or GST. The remaining cell lysates were also resolved by SDS-PAGE and immunoblotted with an antibody to tubulin to show that the amount of protein in the kinase assay was equal Src and anoikis resistance L Wei et al cell lines. As shown in Figure 2a , the phosphorylation of FAK was slightly decreased in the three anoikissensitive cells, but not significantly affected in the anoikis-resistant lung tumor cells upon cell detachment. Src has two major phosphorylation sites at its Cterminus, Tyr-419 and Tyr-530. Phosphorylation of Tyr-419 activates Src whereas that of Tyr-530 inactivates Src. Phospho-specific antibodies towards Src Tyr-419 or Tyr-530 were employed for the assessment of the Src activity. The phosphorylation of Tyr-419 was not significantly affected by cell detachment in the three anoikis-sensitive epithelial cell lines during anoikis. In contrast, the phosphorylations of Tyr-419 in the six anoikis-resistant lung tumor cells were all increased upon cell detachment (Figure 2a ). The phosphorylation of Tyr-530 was not affected by cell detachment. These data suggest that Src may be the protein tyrosine kinase, or at least one of them, that is responsible for the detachment-induced increase of kinase activities in the lung tumor cells and that the increased Src activity may be responsible for the anoikis resistance of the lung tumor cells. These data also suggest that it is a tyrosine kinase, rather than a tyrosine phosphatase that may be involved in the detachment-induced increase of Src activity in the lung tumor cells.
To confirm that Src activity is indeed increased by cell detachment in the tumor cells, we immunoprecipitated Src from various cell lysates and measured the Src activities using an in vitro kinase activity assay. As shown in Figure 2b , the Src activity in the lung tumor cells was generally higher than that in the nontransformed epithelial cells and increased significantly when the lung tumor cells were cultured in suspension. These data further confirm that Src contributes to the detachment-induced increase of protein tyrosine kinase activity in the lung tumor cells.
Src is the predominant member of Src family in the lung tumor cells contributing to the detachment-induced kinase activity
Because the antibody against phospho-Src (Tyr-419) recognizes Src as well as other Src family members, such as Lyn, Yes, and Fyn, we investigated which Src family members contributed to the increase of Src activities upon cell detachment. Src, Lyn, Yes, and Fyn were immunoprecipitated, respectively, with their specific antibodies and were probed with the antibody against the phospho-Tyr 419 of Src. As shown in Figure 3a , phosphorylation of Src was dramatically increased upon cell detachment and phospho-Src was the predominant phosphorylated Src family member in the detached lung tumor cells. The phosphorylation of the other Src family members might also be increased slightly, particularly Yes, upon cell detachment, but they contributed relatively little to the total phosphorylated Tyr-419 of Src in the tumor cells ( Figure 3a) .
To further confirm our observation, we also measured the activities of Src, Yes, Fyn, and Lyn using the in vitro protein tyrosine kinase assay. Similar to the result of the immunoblotting analysis, Src activity was increased significantly upon cell detachment. The activities of Yes, Fyn, and Lyn were too low to be compared in the kinase assay. Taken together, these data suggest that Src, rather than the other Src family members, is the major protein tyrosine kinase that contributes to the celldetachment induced increase of tyrosine kinase activities in the lung tumor cells. However, the role of other Src family members, particularly Yes, can not be ruled out.
Increased Src activities protect the lung adenocarcinoma cells from Anoikis
To address the functional significance of the increased Src activity in the tumor cells in suspension, the cells were treated with an Src-specific inhibitor, pp2, at different concentrations. As shown in Figure 4a and b, pp2 inactivated Src, as indicated by the de-phosphorylation of Src at Tyr-419, and induced apoptosis in the lung tumor cells in a dose-dependent manner. These data strongly suggest that Src activity is essential for the survival of the lung tumor cells in suspension.
To understand whether pp2 specifically induced anoikis, we treated the lung tumor cells cultured in adhesion or in suspension with pp2. At the concentration of 100 mM, pp2 inactivated Src in cells cultured in 
Membrane/cytosol distribution of Src is not altered in the lung tumor cells
To understand the mechanism of the altered regulation of Src in the lung tumor cells, we first examined the changes in subcellular distribution of Src upon cell detachment. We examined the amount of Src proteins in Triton-X100 soluble versus insoluble fractions in both the suspension and the adherent cultures. As shown in Figure 5 , majority of the Src protein were present in the Triton-X100 soluble fraction. Upon cell detachment, there was an increase of Src protein in the Triton-X100 insoluble fraction, suggesting a shift of Src protein from cytosol to membrane in the cells. This distribution and shift, however, was not altered in the anoikis-resistant tumor cells. (100 mM). The cells were lysed and resolved by SDS-PAGE and immunoblotted with the indicated antibodies sequentially (c). Lowmolecular weight DNA was isolated and resolved in 1.5% agarose gel (d) Figure 5 Changes in subcellular localization of Src upon cell detachment. Control MDCK and lung tumor H1792 cells were cultured as attached (A) or in suspension (S) for 24 h. As described in the Materials and methods, proteins were extracted with Triton-X-100 buffer first (Triton-X-100), which is the Triton-X-100 soluble fraction, then extracted with modified RIPA buffer (RIPA), which is the Triton-X-100 insoluble fraction. The extracted proteins were then resolved by SDS-PAGE and immunoblotted with various antibodies sequentially as indicated 
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We next analysed the phosphorylation changes of Src protein in Triton-X100 soluble and insoluble fractions upon cell detachment. The phosphorylation levels of Tyr-419 of Src protein from both Triton-X100 soluble and insoluble fractions were increased upon cell detachment in the tumor cells ( Figure 5 ). The level of phospho-Src (Tyr-419) in the membrane fraction (Triton-X100 insoluble fraction) in the tumor cells, however, was higher than that in the cytosol fraction, suggesting that there is a tyrosine kinase activity in the cell membrane that phosphorylates Src on Tyr-419. There were no significant changes in phosphorylation at Tyr-530 of Src in Triton-X100 soluble and insoluble fractions between the normal and the tumor cells. These data suggest a tyrosine kinase activity in the cell membrane that recruits and phosphorylates Src upon cell detachment. This tyrosine kinase activity may also be increased in the tumor cells and may be responsible for the increased phosphorylation of Src-Tyr-419 upon cell detachment.
Increased PDGFR activity and Src-PDGFR interaction are responsible for the increased Src activity in lung tumor cells upon cell detachment Several structural features of Src and Src-family members facilitate interactions with proteins that regulate Src-family kinase activity. Biochemical and Xray crystallographic analyses have revealed various internal interactions within the Src molecule, which maintain it in an inactive state. These include interactions between the SH2 domain and the carboxylterminal tyrosine, Tyr-530, as well as interactions between the SH3 domain and the SH2-kinase linker. A variety of Src-binding proteins have been detected, which can compete for binding to these components and disturb the intramolecular interactions, allowing for Src kinase activation. The platelet-derived growth factor receptor (PDGFR) (Kypta et al., 1990; Alonso et al., 1995) , epidermal growth factor receptor (EGFR) (Mao et al., 1997) , and focal adhesion kinase (FAK) (Cobb et al., 1994) can all bind to the Src SH2 domain and activate Src.
Since FAK phosphorylation/activity was not upregulated in the lung tumor cells by cell detachment (Figure 2) , we analysed the phosphorylation/activity of PDGFR and EGFR during cell detachment. The phosphorylation of EGFR was decreased in both the nontransformed epithelial cells and the lung tumor cells when they were incubated in suspension (Figure 6 ). In contrast, the phosphorylation of PDGFR was increased in the lung tumor cells upon cell detachment (Figure 6 ), correlated with the changes in Src activity in the lung tumor cells, suggesting that PDGFR, not FAK or EGFR, may be involved in the detachment-induced activation of Src in the lung tumor cells.
We then analysed physical interactions of PDGFR, EGFR, or FAK with Src by co-immunoprecipitation experiments. The binding of FAK to Src was decreased in suspension in both the nontransformed epithelial cells and the lung tumor cells (Figure 7) . No significant binding of EGFR to Src was detected (Figure 7) , further confirming that FAK and EGFR may not be the activators of Src in lung tumor cells in suspension. However, the binding of PDGFR to Src was increased significantly in the lung tumor cells upon cell detachment (Figure 7) , strongly suggesting that PDGFR is possibly the upstream tyrosine kinase that is responsible for the increased Src activity in the lung tumor cells in suspension. To further confirm the role of PDGFR in activating Src, the lung adenocarcinoma cells incubated in suspension were treated with the PDGFR-specific inhibitor, AG17 and the PDGFR specific siRNA. As shown in Figure 8 , AG17 inhibited the phosphorylation of PDGFR as well as the induction of Src phsophorylation and induced anoikis (Figure 8a) . Similarly, the PDGFR siRNA decreased the level of PDGFR and inhibited the detachment-induced Src activation in the lung tumor cells (Figure 8b) .
Taken together, these data strongly suggest that PDGFR is responsible for the detachment-induced Src activation in the lung tumor cells and, along with Src, is responsible for the tumor cells resistance to anoikis.
Activated Src protects lung tumor cells from anoikis through a PI 3K/Akt and MAPK independent pathway
PI 3 kinase/Akt pathway and MAP kinase pathway are the two most important cell survival and proliferation signaling pathways. We tested the involvement of the two pathways in the Src-mediated anoikis resistance of lung tumor cells. As shown in Figure 9 , the Src specific inhibitor pp2 blocked the phosphorylation of Src at Tyr-419 and induced apoptosis, but had no significant effects on the phosphorylation of Akt and MAPK. The slight decrease in phosphorylation of Akt and MAPK on the immunoblot is likely due to the decreased levels of total protein caused by cell death. These data suggest that Src protects the tumor cells from anoikis through pathways independent of Akt and MAPK, which is consistent with our previous observations and other report (Wei et al., 2001; Sithanandam et al., 2003) that inhibition of Akt and MAPK did not induce cell death in the lung tumor cells we analysed. Our data also showed that pp2 had no impacts on the phosphorylation of JNK, p38 MAPK, and FAK, suggesting that these pathways may not be involved in the Src-mediated survival either. There have been reports that Pyk2 may be a substrate of Src (Andreev et al., 2001; Li et al., 2001) . In our study, we found that pp2 could significantly inhibit the phosphorylation of Pyk2 when it induced cell death in the lung tumor cells (Figure 9 ), suggesting that Pyk2 might be a downstream effecter of Src, through which Src functions to protect lung tumor cells from anoikis. Downregulation of Pyk2 could induce anoikis in the lung tumor cells (data not shown). Coll et al. (2002) found that v-Src-induced resistance to anoikis in intestinal epithelial cells is via the increased Bcl-xL Figure 8 (a) Inhibition of Src activation and induction of anoikis of lung adenocarcinoma cells by PDGFR inhibitor. Lung adenocarcinoma cells A549 and H1792 were cultured as attached (A) or in suspension (S) without or with AG17, the PDGFR inhibitor at 100 mM for 24 h. Total cells lysates were analysed by immunoblotting using the indicated antibodies. Phosphorylation of PDGFR was detected with the antibody 4G10 after immunoprecipitation of PDGFR from the total cell lysates. (b) Inhibition of Src activation by PDGFR siRNA. Lung adenocarcinoma cells (H1792) were transfected with a specific PDGFR siRNA or a random control siRNA as described in the Materials and methods. After 48 h culture following the transfection, the cells were reseeded as attached (A) or in suspension (S) for 24 h. Total cell lysates were resolved by SDS-PAGE and analysed by immunoblotting using the indicated antibodies. Phospho-PDGFR was detected with the antibody 4G10 after immunoprecipitation of PDGFR from the total cell lysates Figure 9 Effects of Src specific inhibitor pp2 on phosphorylation of various signaling proteins. Lung adenocarcinoma cells A549 were cultured in suspension for 24 h with or without pp2 at various concentrations as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against phosphorylated (p-) or nonphosphorylated forms of various signaling proteins as indicated. A part of the data shown in this figure was also shown in Figure 4a Src and anoikis resistance L Wei et al expression. Ogata et al. (2003) recently reported that Pyk2 is involved in the upregulation of Bcl-xL expression and has an antiapoptotic effect. All these support that Pyk2 might be a key molecule in the Src-mediated cell survival pathway.
Discussion
Anoikis resistance or anchorage-independent survival and growth is a hallmark of tumor cells. This property of tumor cells suggests altered activities in tumor cells that compensates for the cell survival signals lost by disrupting cell-matrix interactions. However, the exact mechanisms that are responsible for anoikis resistance of naturally occurring human cancer cells have not been clearly understood. There have been some studies regarding the role of Src in anoikis. Windham et al. (2002) reported that Src activation is important for the human colon tumor cells' resistance to anoikis. Frisch and Francis (1994) discovered that anoikis is abrogated in epithelial cells by transformation with v-Src. Hisano et al. (2003) found that v-Src can suppress anoikis in human gallbladder epithelial cells. Coll et al. (2002) proposed that v-Src-induced resistance to anoikis in intestinal epithelial cells is via the increased Bcl-xL expression. These reports suggest that Src plays an important role in anoikis resistance. Our previous study has demonstrated that tyrosine kinase activities are critical for anoikis resistance of lung tumor cells (Wei et al., 2001) . In this study, we further identified Src as one of the important tyrosine kinases that were responsible for the anchorage-independent survival of the tumor cells. More importantly, we found that the regulation of Src was altered in the human lung cancer cells. There is a dramatic increase of Src activity in the anoikis-resistant tumor cells when they are detached from their substratum. This cell detachment-induced Src activation may be common to cancer cells since we observed elevated Src activity upon cell detachment in all the anoikis-resistant lung tumor cell lines we have analysed. This increased Src activity is critical for the tumor cells to survive in suspension. Our study not only demonstrates the importance of Src in the lung tumor cells' resistance to anoikis, but also suggests a novel mechanism in activating Src in lung tumor cells.
The specific induction of anoikis in lung tumor cells by Src inhibitor is very intriguing. It suggests that Src is a necessary and critical survival factor for tumor cells in suspension, but not for those growing under adherent condition. There appears to be a pathway parallel to and independent of Src. This pathway supports the survival and growth of adherent cells and is dependent on cellmatrix interactions under adherent condition. The increased Src activity in the tumor cells in suspension compensates for the loss of this pathway, which transducts cell survival signals from cell-matrix interactions. This tumor cell-specific activation of Src may be an ideal target for anticancer drug intervention.
An important mechanism in regulating Src activity is through control of its phosphorylation status. There are two major phosphorylation sites present in the Cterminus of human c-Src, Tyr-419 (Tyr-416 in chicken) and Tyr-530 (Tyr-527 in chicken) (Bjorge et al., 2000; Jones et al., 2000) . Phosphorylation of Tyr-419 activates Src whereas that of Tyr-530 inactivates Src. In our study, we did not observe a change in phosphorylation of Tyr-530/527 upon detachment, suggesting that dephosphorylation of Tyr-530/527 is not the major mechanism for the detachment-induced increase of Src activity in the lung tumor cells. But we did note that phosphorylation of Tyr-419/416 was increased significantly in the tumor cells in suspension, indicating that increased Src activity upon cell detachment is mainly through the phosphorylation of Tyr-419/416 of Src.
Previous studies showed that the Tyr-419/416 is a target for intermolecular autophosphorylation (Smart et al., 1981) and may also be a target of other tyrosine kinases, resulting in Src activation (Chiang and Sefton, 2000) . Phosphorylation of Tyr-419/416 can also activate Src activity in the context of simultaneous phosphorylation at Tyr-530/527 (Boerner et al., 1996; Sun et al., 1998) , suggesting that active Src phosphorylated at Tyr-419/416 can not be fully inactivated by phosphorylation at Tyr-530/527 alone. This supports the findings that inactive Src may be the target of other kinases that can phosphorylate Tyr-419/416 and cause Src activation (Chiang and Sefton, 2000) . There have been studies showing that EGFR (Mao et al., 1997) , PDGFR (Kypta et al., 1990; Alonso et al., 1995) , and FAK (Cobb et al., 1994) are the kinases which can bind to the Src SH2 domain and activate Src. In our study, we found that FAK and EGFR activities were decreased upon cell detachment in both the nontransformed epithelial cells and the lung tumor cells, suggesting that they may not be the upstream kinases responsible for the detachmentinduced increase of Src activity. Similarly, the binding of FAK to Src was decreased upon cell detachment in both the anoikis-sensitive and resistant cells. There was no significant binding of EGFR to Src detected in these cells, further confirming that FAK and EGFR may not be the activators for Src in the lung tumor cells in suspension. In contrast, the phosphorylation of PDGFR and the binding of PDGFR to Src were all increased in the lung tumor cells in suspension, suggesting that PDGFR may be the upstream protein tyrosine kinase that phosphorylates Tyr-419/416 and activates Src. Inhibition of PDGFR with its specific inhibitor and siRNA could block the detachment-induced Src activation, further confirming that PDGFR is indeed involved in the detachment-induced increase of Src activity in the lung tumor cells.
We also observed a shift of Src from Triton-soluble fraction to Triton-insoluble fraction of cell lysates, which suggests a translocation of Src from cytosol to membrane, when cells are detached. It has been reported that activated Src is translocated from cytosol to focal adhesions through an actin and SH3 domain-dependent mechanism (Fincham et al., 1996 (Fincham et al., , 2000 Fincham and Frame, 1998) . The function of the translocation observed in our study is not clear at present. However, this translocation is not altered in tumor cells, and the translocation per se does not seem to be sufficient to activate Src in our study. Taken together, these observations lead us to propose a model for the induction of Src activity by cell detachment in tumor cells. Cell detachment induces a cytosol to membrane translocation of Src and an activation of PDGFR in the tumor cells. The translocated Src then interacts with the activated PDGFR, which in turn phosphorylates Src at Tyr-419 and activates Src. Our study also revealed that other Src family members may also be activated by the cell detachment, but Src is the major kinase contributing to the detachment-induced increase of kinase activity in the lung tumor cells.
The binding of various proteins to Src is also an important mechanism in regulating Src activity by competing for binding to Src SH2 or SH3 domains and disturbing the intramolecular interactions of Src. P130Cas has been reported to bind to Src SH2 and SH3 domains resulting in Src activation (Burnham et al., 2000) . In the present study, we found an increased binding of Src to p130Cas in the lung tumor cells upon cell detachment, which is consistent with our previous observation that a difference in p130Cas phsophorylation was observed between the nontransformed epithelial cells and lung tumor cells (Wei et al., 2002) . These data suggest that the interaction between Src and p130Cas could be another mechanism that contributes to the detachment-induced increase of Src activity.
The initial events that triggered the activation of PDGFR and association of Src with PDGFR and p130Cas upon cell detachment have not been understood. We observed that the anoikis-resistant tumor cells tend to form aggregates when they were detached and cultured in suspension (data not shown). There have been reports that apoptosis was inversely correlated with cell aggregation (Aoshiba et al., 1997; Valentinis et al., 1998) . Whether the cell aggregation can activate PDGFR and lead to subsequent activation of Src remains to be seen.
In summary, we showed in this study for the first time that Src activity is increased by detachment of human lung tumor cells from their substratum. Increased Src activities upon cell detachment in the lung tumor cells compensate for the loss of cell survival signals from cellmatrix interactions and support the survival of lung tumor cells in suspension. It seems that Src does not function through MAPK or PI 3K/Akt pathways to protect lung tumor cells from anoikis and Pyk2 appears to be the key downstream effecter of Src in mediating the cell survival signals in the lung tumor cells in suspension. PDGFR acts as the upstream protein tyrosine kinase of Src and is responsible for the detachment-induced increase of Src activity.
Materials and methods
Cell culture and anoikis assay
Immortalized human bronchial epithelial cell line HBE 4-E6/ E7 and Madin-Darby canine kidney epithelial cell line MDCK and lung adenocarcinoma cell lines A549, H1792, SK-LU-1, H522, H1437, H460, and Calu-3 were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells, except HBE4-E6/E7, were maintained in DMEM (Life Technologies, Inc., Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum. HBE4-E6/E7 was cultured in Keratinocyte-SFM supplemented with brain pituitary extracts and human recombinant EGF as suggested by the manufacturer (GIBCO-BRL, Grand Island, NY, USA).
Anoikis assay was essentially performed as described by Frisch and Francis (1994) . Briefly, cells were grown to confluence in 100-mm tissue culture dishes. Cells were then trypsinized, counted, and 10 6 cells were plated into 60-mm polyHEMA-coated Petri dishes. The polyHEMA-coated dishes were prepared by applying 2-ml polyHEMA solution (10 mg/ml polyhydroxyethylmethacrylate, Aldrich Chemical Co., Milwaukee, WI, USA in ethanol) onto the dish, dried in tissue culture hood, repeated once, followed by extensive wash with PBS (>3 times). Cells cultured in the polyHEMA dishes were collected by pipetting; cells cultured in regular tissue culture dishes were collected by scraping. Cytosolic nucleic acids, which contain both fragmented genomic DNA and RNA, were extracted with 0.6-ml cell lysis buffer containing 0.5% Triton X-100, 10 mM EDTA, and 10 mM Tris (pH 7.4). The cell lysates were pheno-chloroform extracted three times, ethanol precipitated, and analysed on a 1.5% agarose gel. The gel was incubated in RNase A-containing solution (5 mg/ml) to digest away the RNAs before photographing.
Antibodies, western blotting, and immunoprecipitation
Mouse monoclonal antibody against tyrosine-phosphorylated proteins (4G10) was purchased from UpState Biotechnology (Lake Placid, NY, USA). Rabbit antibodies against phosphoSrc (Tyr-419), phospho-Src (Tyr-530), phospho-Pyk2 (Tyr-402) were purchased from BioSource (Camarillo, CA, USA). Mouse monoclonal antibodies against p130Cas, FAK, phospho-FAK (Tyr-397) were purchased from BD Transduction Laboratory (San Diego, CA, USA). Mouse monoclonal antibodies to Src, Fyn, Lyn, or Lck, and rabbit antibody to PDGFR-b was purchased from Santa Cruze Biotech Inc. (Santa Cruze, CA, USA). Rabbit polyclonal antibodies to phospho-Akt, Akt, phospho-MAPK, and MAPK were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse monoclonal antibody to PARP was from Pharmagen (San Diego, CA, USA). All commercially purchased antibodies were used as recommended by the manufacturers.
For Western blotting, cells were lysed in a modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 0.5% (w/v) sodium deoxycholate, 0.1% SDS, 0.2 mM phenylmethylsulfonyl fluoride, leupeptin (5 mg/ml), aprotinin (5 mg/ ml), and 1 mM Na 3 VO 4 ). Cell nuclei were removed from lysates by centrifugation for 10 min and the cell lysates were normalized for protein concentrations by using the Bradford reagent (Bio-Rad, Hercules, CA, USA). Lysate (30 mg) was resolved by SDS-PAGE (7.5%) and transferred onto a nitrocellulose membrane. The membrane was blocked with 5% fat-free milk in TBST (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.1% (v/v) Tween 20) for 1 h at room temperature and then incubated with a primary antibody at 41C overnight. The membrane was then washed three times in TBST and incubated for 1 h at room temperature with the horseradish peroxidase-conjugated secondary antibody (Promega, Madison, WI, USA), followed by ECL detection (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
For immunoprecipitation studies, cell lysates were precleared with protein A-agarose and/or protein G-agarose beads (Santa Cruz Biotech, Santa Cruz, CA, USA), incubated with the specific antibodies at 41C for 2 h, and immunoprecipitated with protein A-agarose and/or protein G-agarose beads (Santa Cruz Biotech, Santa Cruz, CA, USA) at 41C for another 2 h with constant rotation.
In vitro kinase assay
For measuring the tyrosine kinase activities of the total cell lysates, cells were lysed in NP40 buffer containing 0.5%. NP-40, 1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride, leupeptin (5 mg/ml), aprotinin (5 mg/ml), and 1 mM Na 3 VO 4 . The bacterial-expressed p130Cas-GST fusion protein was used as the substrate. In total, 10 ml of the above total cell lysates containing same amount of protein were mixed in 60 ml kinase buffer containing 10 mg p130Cas-GST fusion protein, 200 mM ATP, 25 mM Tris-HCl (pH 7.5), 5 mM b-glycerophosphate, 2 mM DTT, 0.1 mM Na 3 VO 4 , 10mM MgCl 2 , and incubated at 301C for 30 min. After kinase reaction, 2 Â Laemmli sample buffer were added and the samples were resolved by 7.5% SDS-PAGE, transferred onto a nitrocellulose membrane, and analysed by immunoblotting with the antiphosphotyrosine antibody 4G10.
In vitro tyrosine kinase activity assay
In vitro tyrosine kinase assay was carried out using a Tyrosine Kinase Activity Assay Kit from Chemicon International (Temecula, CA, USA). Briefly, cells were lysed with RIPA buffer and Src or its family members (Lyn, Fyn, and Yes) were immunoprecipitated with their specific antibodies from the total cell lysates. The obtained precipitates were incubated with 0.1 mg of biotinylated poly[Glu : Tyr] 4 : 1 peptides as the substrate in 50 ml kinase assay buffer containing 1 mM ATP, 10 mM MgCl 2 , 25 mM Tris-HCl (pH 7.5), 5 mM b-glycerophosphate, 2 mM DTT, and 0.1 mM Na 3 VO 4 , at 301C for 30 min. The reaction was terminated with 10 ml of 120 mM EDTA. The phosphorylation levels of the peptides were measured by ELISA and the absorbance of each microwell was read on a standard microplate reader at 450 nm wavelength. The obtained optical density (OD450 nm) values represent the relative activity of the tyrosine kinases.
Preparation of cytoplasmic and cytoskeletal fractions of cell lysates
Triton X-100 soluble (cytoplasmic/cytosol) and insoluble (cytoskeletal/membrane) fractions were prepared as previously described (Carragher et al., 1999) . In brief, cells were lysed in Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.4, 1% Triton X-100, 5 mM EGTA, 0.4 mM leupeptin, 0.2 mM Na 3 VO 4 , and 0.1 mM PMSF) for 1 h at 41C. Triton X-100 insoluble and soluble extracts were separated by centrifugation at 15 000 g for 5 min. The cytoskeletal pellet was washed twice with Triton-free lysis buffer, and proteins were extracted using RIPA buffer (10 mM Tris-HCl (pH 7.2), 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 1 mM PMSF, and 1 mM Na 3 VO 4 ).
Treatment of cells with PDGFR inhibitor
The specific PDGFR inhibitor, AG17 was purchased from Calbiochem (La Jolla, CA, USA) and dissolved in DMSO. In experiments that cells were treated with the inhibitor, the same volumes of DMSO were added to the controls.
Transfection of siRNA
PDGFR siRNA SMARTpoolt reagents were purchased from Dharmacon (Lafayette, CO, USA), which contains four pooled PDGFR specific siRNA duplexes of 21-nucleotide RNA oligonucleotides. A negative control containing four pooled nonsilencing, nonspecific siRNA duplexes was also purchased from the same company. Transfection of siRNA was performed using siPORT Amine transfection reagent (Ambion, Austin, TX, USA). All assays were performed 48 h post-transfection.
